Some of the drugs currently used for Coronavirus disease (COVID-19) may have interaction with myocardial cells, and may results in QTc interval prolongation and torsade de pointes. Aim of the study was therefore to evaluate potential predictors of QTc-interval prolongation and incidence of life threating arrhythmias in COVID-19 patients admitted with normal QTc-interval that started therapy during hospitalization.We report one of the first multi-center registry on 154 consecutive patients with a diagnosis of COVID-19 from February 25 to March 30 2020, admitted into four hospitals in Italy and Germany. All patients underwent standard 12-lead ECGs were serially recorded within 12 hours after admission and then repeated after 7 and 14 days. We found that: 1) After 7 days of hospitalization 14 % of patients developed prolongation of QTc interval, dual antiviral therapy, age and basal heart rate were an independent predictor of pQT; 2) Life threatening arrhythmias have an incidence of 3.6% and may present after a median of 9 days of hospitalization with cardiac arrest and non-sustained VT; 3) Life threatening arrhythmias were featured by poor outcome with 50% of mortality. The study evaluated a relatively low number of patients. Dual antiviral therapy, age and basal heart rate were the only independent predictors of QT prolongation at 7 days. In the present study we found that a combination of antivirals may predict prolonged QTc interval, however due to the heterogenous antivirals combination, no conclusion can be provided.